Switch to:
Also traded in: Argentina, Brazil, Chile, France, Germany, Mexico, Romania, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.50
MRK's Cash to Debt is ranked lower than
74% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.33 vs. MRK: 0.50 )
Ranked among companies with meaningful Cash to Debt only.
MRK' s Cash to Debt Range Over the Past 10 Years
Min: 0.32  Med: 0.68 Max: 2.45
Current: 0.5
0.32
2.45
Equity to Asset 0.44
MRK's Equity to Asset is ranked lower than
75% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. MRK: 0.44 )
Ranked among companies with meaningful Equity to Asset only.
MRK' s Equity to Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.44 Max: 0.53
Current: 0.44
0.34
0.53
Interest Coverage 10.67
MRK's Interest Coverage is ranked lower than
61% of the 475 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.69 vs. MRK: 10.67 )
Ranked among companies with meaningful Interest Coverage only.
MRK' s Interest Coverage Range Over the Past 10 Years
Min: 3.31  Med: 9.85 Max: 20.11
Current: 10.67
3.31
20.11
F-Score: 7
Z-Score: 3.16
M-Score: -2.75
WACC vs ROIC
6.54%
10.57%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 18.42
MRK's Operating margin (%) is ranked higher than
79% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.73 vs. MRK: 18.42 )
Ranked among companies with meaningful Operating margin (%) only.
MRK' s Operating margin (%) Range Over the Past 10 Years
Min: 5.15  Med: 15.81 Max: 21.86
Current: 18.42
5.15
21.86
Net-margin (%) 11.72
MRK's Net-margin (%) is ranked higher than
70% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.01 vs. MRK: 11.72 )
Ranked among companies with meaningful Net-margin (%) only.
MRK' s Net-margin (%) Range Over the Past 10 Years
Min: 1.87  Med: 13.30 Max: 47.04
Current: 11.72
1.87
47.04
ROE (%) 10.11
MRK's ROE (%) is ranked higher than
61% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.15 vs. MRK: 10.11 )
Ranked among companies with meaningful ROE (%) only.
MRK' s ROE (%) Range Over the Past 10 Years
Min: 1.52  Med: 14.91 Max: 42.27
Current: 10.11
1.52
42.27
ROA (%) 4.50
MRK's ROA (%) is ranked higher than
54% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.68 vs. MRK: 4.50 )
Ranked among companies with meaningful ROA (%) only.
MRK' s ROA (%) Range Over the Past 10 Years
Min: 0.79  Med: 6.50 Max: 16.34
Current: 4.5
0.79
16.34
ROC (Joel Greenblatt) (%) 46.34
MRK's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.13 vs. MRK: 46.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MRK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 10.88  Med: 45.71 Max: 105.49
Current: 46.34
10.88
105.49
Revenue Growth (3Y)(%) -3.30
MRK's Revenue Growth (3Y)(%) is ranked lower than
75% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. MRK: -3.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MRK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -24  Med: 3.60 Max: 23.1
Current: -3.3
-24
23.1
EBITDA Growth (3Y)(%) -6.40
MRK's EBITDA Growth (3Y)(%) is ranked lower than
75% of the 553 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. MRK: -6.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MRK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -15.7  Med: 6.10 Max: 25.8
Current: -6.4
-15.7
25.8
EPS Growth (3Y)(%) -7.90
MRK's EPS Growth (3Y)(%) is ranked lower than
69% of the 510 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. MRK: -7.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MRK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -42.7  Med: 0.20 Max: 73.8
Current: -7.9
-42.7
73.8
» MRK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

MRK Guru Trades in Q3 2015

Joel Greenblatt 5,844 sh (New)
Richard Snow 860,145 sh (+15902.70%)
Ray Dalio 251,746 sh (+1368.68%)
Paul Tudor Jones 44,663 sh (+164.28%)
PRIMECAP Management 2,645,000 sh (+29.53%)
Vanguard Health Care Fund 49,743,388 sh (+8.73%)
Murray Stahl 43,271 sh (+5.15%)
Pioneer Investments 3,427,061 sh (+4.51%)
Ruane Cunniff 4,994 sh (+4.39%)
Mairs and Power 104,124 sh (+1.22%)
David Carlson 250,000 sh (unchged)
First Eagle Investment 9,050 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Prem Watsa 12,000 sh (unchged)
Tom Russo Sold Out
David Dreman Sold Out
Kyle Bass Sold Out
RS Investment Management Sold Out
Dodge & Cox 24,585,258 sh (-0.39%)
T Rowe Price Equity Income Fund 6,571,200 sh (-0.82%)
Charles Brandes 2,791,984 sh (-0.90%)
Kahn Brothers 1,006,208 sh (-1.02%)
Ken Fisher 6,761,706 sh (-1.09%)
Barrow, Hanley, Mewhinney & Strauss 25,179,076 sh (-1.80%)
Jeff Auxier 141,489 sh (-2.51%)
Manning & Napier Advisors, Inc 6,178,367 sh (-2.66%)
Mario Gabelli 142,715 sh (-3.92%)
Signature Select Canadian Fund 154,400 sh (-4.28%)
NWQ Managers 69,835 sh (-5.36%)
Jim Simons 1,461,734 sh (-23.94%)
Jeremy Grantham 4,200 sh (-35.38%)
» More
Q4 2015

MRK Guru Trades in Q4 2015

John Buckingham 24,665 sh (New)
Tom Russo 3,836 sh (New)
Joel Greenblatt 753,471 sh (+12793.07%)
Jim Simons 1,752,234 sh (+19.87%)
Richard Snow 998,514 sh (+16.09%)
Jeff Auxier 153,403 sh (+8.42%)
Charles Brandes 3,012,572 sh (+7.90%)
Barrow, Hanley, Mewhinney & Strauss 26,655,176 sh (+5.86%)
PRIMECAP Management 2,790,000 sh (+5.48%)
Vanguard Health Care Fund 50,476,700 sh (+1.47%)
Ken Fisher 6,822,070 sh (+0.89%)
Mairs and Power 104,637 sh (+0.49%)
Kahn Brothers 1,010,927 sh (+0.47%)
Jeremy Grantham 4,200 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Ruane Cunniff 4,994 sh (unchged)
David Carlson 250,000 sh (unchged)
Prem Watsa Sold Out
Dodge & Cox 24,563,150 sh (-0.09%)
Murray Stahl 43,031 sh (-0.55%)
NWQ Managers 68,615 sh (-1.75%)
Mario Gabelli 139,615 sh (-2.17%)
Paul Tudor Jones 40,561 sh (-9.18%)
First Eagle Investment 7,790 sh (-13.92%)
T Rowe Price Equity Income Fund 5,610,000 sh (-14.63%)
Ray Dalio 156,246 sh (-37.94%)
Pioneer Investments 989,884 sh (-71.12%)
Manning & Napier Advisors, Inc 578,810 sh (-90.63%)
» More
Q1 2016

MRK Guru Trades in Q1 2016

David Dreman 710 sh (New)
John Burbank 1,370,117 sh (New)
Richard Pzena 921,365 sh (New)
Paul Tudor Jones 714,430 sh (+1661.37%)
First Eagle Investment 16,090 sh (+106.55%)
Joel Greenblatt 1,248,557 sh (+65.71%)
Ray Dalio 210,746 sh (+34.88%)
PRIMECAP Management 2,992,800 sh (+7.27%)
Murray Stahl 45,497 sh (+5.73%)
John Buckingham 25,885 sh (+4.95%)
Barrow, Hanley, Mewhinney & Strauss 26,663,511 sh (+0.03%)
Robert Bruce 259,400 sh (unchged)
Tom Russo 3,836 sh (unchged)
David Carlson 250,000 sh (unchged)
Jeremy Grantham Sold Out
NWQ Managers Sold Out
Jeff Auxier 153,303 sh (-0.07%)
Dodge & Cox 24,543,704 sh (-0.08%)
Charles Brandes 3,000,058 sh (-0.42%)
Ken Fisher 6,698,235 sh (-1.82%)
Ruane Cunniff 4,894 sh (-2.00%)
Kahn Brothers 985,419 sh (-2.52%)
Mairs and Power 101,850 sh (-2.66%)
Signature Select Canadian Fund 149,400 sh (-3.24%)
Vanguard Health Care Fund 48,728,100 sh (-3.46%)
Pioneer Investments 925,463 sh (-6.51%)
Richard Snow 911,027 sh (-8.76%)
Manning & Napier Advisors, Inc 501,558 sh (-13.35%)
Mario Gabelli 118,145 sh (-15.38%)
T Rowe Price Equity Income Fund 4,702,900 sh (-16.17%)
Jim Simons 484,334 sh (-72.36%)
» More
Q2 2016

MRK Guru Trades in Q2 2016

T Rowe Price Equity Income Fund 3,500,000 sh (-25.58%)
» More
» Details

Insider Trades

Latest Guru Trades with MRK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:OTCPK:NVSEF, NYSE:BMY, NYSE:SNY, OTCPK:GLAXF, NYSE:ABBV, NYSE:PFE, NYSE:LLY, OTCPK:BAYZF, NYSE:AZN, OTCPK:ALPMY, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:OPHLY, OTCPK:DSNKY, OTCPK:KYKOF, OTCPK:SNPHF, OTCPK:CHJTF, OTCPK:PTKFF, OTCPK:GWPRF, OTCPK:MAYNF » details
Traded in other countries:MRK.Argentina, MRCK34.Brazil, MRK.Chile, MRK.France, 6MK.Germany, MRK.Mexico, MRK.Romania, MRK.Switzerland, 0QAH.UK,
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.

Merck & Co Inc was incorporated in New Jersey in 1970. The Company is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Company's operations are managed on a products basis and are comprised of four operating segments, the Pharmaceutical, Animal Health, Alliances and Healthcare Services segments. The Pharmaceutical segment is the only reportable segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, administered at physician offices. The Company sells these human health vaccines to physicians, wholesalers, physician distributors and government entities. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. The Alliances segment includes results from the Company's relationship with AstraZeneca LP until the termination of that relationship on June 30, 2014. The Company's Healthcare Services segment provides services and solutions that focus on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company's pharmaceutical products include therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Products within the Company's franchises are - Primary Care and Women's Health include Cardiovascular, Diabetes, and General Medicine and Women's Health; Hospital and Specialty include Hepatitis, HIV, Hospital Acute Care, and Immunology; Oncology includes Keytruda, Emend, Temodar, and Temodal; Diversified Brands includes Respiratory and Others; and Vaccines. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. Principal products in this segment include - Livestock Products; Poultry Products; Companion Animal Products; and Aquaculture Products. The Company's competitors include other research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, generic drug manufacturers and animal health care companies.

Ratios

vs
industry
vs
history
P/E(ttm) 36.18
MRK's P/E(ttm) is ranked lower than
61% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.41 vs. MRK: 36.18 )
Ranked among companies with meaningful P/E(ttm) only.
MRK' s P/E(ttm) Range Over the Past 10 Years
Min: 6.33  Med: 19.92 Max: 138.33
Current: 36.18
6.33
138.33
Forward P/E 15.77
MRK's Forward P/E is ranked higher than
57% of the 81 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.39 vs. MRK: 15.77 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 36.18
MRK's PE(NRI) is ranked lower than
60% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.39 vs. MRK: 36.18 )
Ranked among companies with meaningful PE(NRI) only.
MRK' s PE(NRI) Range Over the Past 10 Years
Min: 6.33  Med: 19.92 Max: 138.33
Current: 36.18
6.33
138.33
Price/Owner Earnings (ttm) 19.92
MRK's Price/Owner Earnings (ttm) is ranked higher than
73% of the 282 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.57 vs. MRK: 19.92 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MRK' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 6.1  Med: 15.67 Max: 48.31
Current: 19.92
6.1
48.31
P/B 3.68
MRK's P/B is ranked lower than
61% of the 823 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. MRK: 3.68 )
Ranked among companies with meaningful P/B only.
MRK' s P/B Range Over the Past 10 Years
Min: 1.72  Med: 3.21 Max: 7.25
Current: 3.68
1.72
7.25
P/S 4.20
MRK's P/S is ranked lower than
63% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.74 vs. MRK: 4.20 )
Ranked among companies with meaningful P/S only.
MRK' s P/S Range Over the Past 10 Years
Min: 2.02  Med: 3.25 Max: 5.48
Current: 4.2
2.02
5.48
PFCF 15.21
MRK's PFCF is ranked higher than
71% of the 221 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.52 vs. MRK: 15.21 )
Ranked among companies with meaningful PFCF only.
MRK' s PFCF Range Over the Past 10 Years
Min: 7.87  Med: 15.74 Max: 89.14
Current: 15.21
7.87
89.14
POCF 13.50
MRK's POCF is ranked higher than
61% of the 292 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.35 vs. MRK: 13.50 )
Ranked among companies with meaningful POCF only.
MRK' s POCF Range Over the Past 10 Years
Min: 6.67  Med: 13.05 Max: 35.89
Current: 13.5
6.67
35.89
EV-to-EBIT 27.71
MRK's EV-to-EBIT is ranked lower than
66% of the 591 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.71 vs. MRK: 27.71 )
Ranked among companies with meaningful EV-to-EBIT only.
MRK' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.9  Med: 14.40 Max: 52.6
Current: 27.71
4.9
52.6
EV-to-EBITDA 13.86
MRK's EV-to-EBITDA is ranked higher than
61% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.97 vs. MRK: 13.86 )
Ranked among companies with meaningful EV-to-EBITDA only.
MRK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.2  Med: 8.50 Max: 20.4
Current: 13.86
4.2
20.4
PEG 3.95
MRK's PEG is ranked lower than
70% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.01 vs. MRK: 3.95 )
Ranked among companies with meaningful PEG only.
MRK' s PEG Range Over the Past 10 Years
Min: 0.52  Med: 2.69 Max: 28.55
Current: 3.95
0.52
28.55
Shiller P/E 25.45
MRK's Shiller P/E is ranked higher than
77% of the 151 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 50.39 vs. MRK: 25.45 )
Ranked among companies with meaningful Shiller P/E only.
MRK' s Shiller P/E Range Over the Past 10 Years
Min: 8.24  Med: 15.80 Max: 27.43
Current: 25.45
8.24
27.43
Current Ratio 1.64
MRK's Current Ratio is ranked lower than
68% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. MRK: 1.64 )
Ranked among companies with meaningful Current Ratio only.
MRK' s Current Ratio Range Over the Past 10 Years
Min: 1.07  Med: 1.59 Max: 3.7
Current: 1.64
1.07
3.7
Quick Ratio 1.35
MRK's Quick Ratio is ranked lower than
63% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. MRK: 1.35 )
Ranked among companies with meaningful Quick Ratio only.
MRK' s Quick Ratio Range Over the Past 10 Years
Min: 0.8  Med: 1.26 Max: 3.44
Current: 1.35
0.8
3.44
Days Inventory 125.94
MRK's Days Inventory is ranked lower than
57% of the 666 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.20 vs. MRK: 125.94 )
Ranked among companies with meaningful Days Inventory only.
MRK' s Days Inventory Range Over the Past 10 Years
Min: 104.23  Med: 130.49 Max: 205.17
Current: 125.94
104.23
205.17
Days Sales Outstanding 63.48
MRK's Days Sales Outstanding is ranked higher than
59% of the 624 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.90 vs. MRK: 63.48 )
Ranked among companies with meaningful Days Sales Outstanding only.
MRK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.5  Med: 58.77 Max: 87.87
Current: 63.48
44.5
87.87
Days Payable 54.76
MRK's Days Payable is ranked lower than
64% of the 578 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.26 vs. MRK: 54.76 )
Ranked among companies with meaningful Days Payable only.
MRK' s Days Payable Range Over the Past 10 Years
Min: 30.2  Med: 44.78 Max: 90.82
Current: 54.76
30.2
90.82

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.12
MRK's Dividend Yield is ranked higher than
79% of the 603 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. MRK: 3.12 )
Ranked among companies with meaningful Dividend Yield only.
MRK' s Dividend Yield Range Over the Past 10 Years
Min: 2.51  Med: 3.82 Max: 6.68
Current: 3.12
2.51
6.68
Dividend Payout 1.12
MRK's Dividend Payout is ranked lower than
70% of the 379 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. MRK: 1.12 )
Ranked among companies with meaningful Dividend Payout only.
MRK' s Dividend Payout Range Over the Past 10 Years
Min: 0.15  Med: 0.51 Max: 4.22
Current: 1.12
0.15
4.22
Dividend Growth (3y) 2.30
MRK's Dividend Growth (3y) is ranked lower than
63% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. MRK: 2.30 )
Ranked among companies with meaningful Dividend Growth (3y) only.
MRK' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 2.80 Max: 14.8
Current: 2.3
0
14.8
Forward Dividend Yield 3.15
MRK's Forward Dividend Yield is ranked higher than
78% of the 578 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. MRK: 3.15 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.74
MRK's Yield on cost (5-Year) is ranked higher than
75% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.93 vs. MRK: 3.74 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MRK' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3.01  Med: 4.58 Max: 8.01
Current: 3.74
3.01
8.01
3-Year Average Share Buyback Ratio 2.80
MRK's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 422 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. MRK: 2.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MRK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13  Med: 1.10 Max: 2.8
Current: 2.8
-13
2.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 34.88
MRK's Price/Tangible Book is ranked lower than
98% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.59 vs. MRK: 34.88 )
Ranked among companies with meaningful Price/Tangible Book only.
MRK' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.19  Med: 12.79 Max: 3112.5
Current: 34.88
3.19
3112.5
Price/Projected FCF 1.33
MRK's Price/Projected FCF is ranked higher than
78% of the 344 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.59 vs. MRK: 1.33 )
Ranked among companies with meaningful Price/Projected FCF only.
MRK' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.75  Med: 1.23 Max: 3.04
Current: 1.33
0.75
3.04
Price/Median PS Value 1.30
MRK's Price/Median PS Value is ranked lower than
61% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.14 vs. MRK: 1.30 )
Ranked among companies with meaningful Price/Median PS Value only.
MRK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.65  Med: 1.21 Max: 2
Current: 1.3
0.65
2
Price/Peter Lynch Fair Value 4.09
MRK's Price/Peter Lynch Fair Value is ranked lower than
84% of the 173 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. MRK: 4.09 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MRK' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.55  Med: 1.64 Max: 10.48
Current: 4.09
0.55
10.48
Price/Graham Number 7.48
MRK's Price/Graham Number is ranked lower than
91% of the 500 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.19 vs. MRK: 7.48 )
Ranked among companies with meaningful Price/Graham Number only.
MRK' s Price/Graham Number Range Over the Past 10 Years
Min: 1.09  Med: 3.91 Max: 31.92
Current: 7.48
1.09
31.92
Earnings Yield (Greenblatt) (%) 3.64
MRK's Earnings Yield (Greenblatt) (%) is ranked higher than
55% of the 844 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. MRK: 3.64 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MRK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.9  Med: 7.00 Max: 20.6
Current: 3.64
1.9
20.6
Forward Rate of Return (Yacktman) (%) 14.00
MRK's Forward Rate of Return (Yacktman) (%) is ranked higher than
63% of the 325 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. MRK: 14.00 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MRK' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -5.7  Med: 6.60 Max: 22.2
Current: 14
-5.7
22.2

More Statistics

Revenue (TTM) (Mil) $39,385
EPS (TTM) $ 1.62
Beta0.75
Short Percentage of Float1.16%
52-Week Range $45.69 - 60.07
Shares Outstanding (Mil)2,768.03

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 39,202 38,702 39,856
EPS ($) 3.70 3.75 3.88
EPS w/o NRI ($) 3.70 3.75 3.88
EPS Growth Rate
(3Y to 5Y Estimate)
4.25%
Dividends Per Share ($) 1.81 1.83 1.86
» More Articles for NYSE:MRK

Headlines

Articles On GuruFocus.com
T. Rowe Price Equity Income Fund Sells Apache, Johnson & Johnson in 2nd Quarter Jul 21 2016 
Technology Earnings Helping Market to Gain Jul 20 2016 
An Unfair Valuation Makes a Great Investment Jul 15 2016 
5 Overvalued Dow Components Jul 15 2016 
Stocks Higher After Release of FOMC Minutes Jul 07 2016 
Merck CEO Sells 60,000 Company Shares Jul 06 2016 
Market Indexes Higher With Volatility Lower May 25 2016 
The PBM Empire Strikes Back May 10 2016 
U.S. Stocks Trade Flat at Start of Week May 09 2016 
Market Indexes Flat as Economic Indicators Still Point Lower May 08 2016 

More From Other Websites
Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China Jul 28 2016
Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China Jul 28 2016
A Powerful New Antibiotic May Have Been Living in Our Noses This Whole Time Jul 27 2016
Can Keytruda Deliver Earnings Growth For Merck? Jul 27 2016
Merck’s 2Q16 Estimates: Expect Operational Growth in Revenues Jul 27 2016
Short Sellers Get Selective on Major Pharma Jul 27 2016
What to Expect from Merck’s 2Q16 Earnings Jul 27 2016
[$$] From Farm to Pharma, Former CEO Recalls First Job as Laborer Jul 27 2016
FDA enhances warnings on group of strong antibiotics Jul 26 2016
Merck Announces Fourth-Quarter 2016 Dividend Jul 26 2016
Merck Announces Fourth-Quarter 2016 Dividend Jul 26 2016
[$$] Former CEO Recalls First Job as Farm Laborer Jul 26 2016
Merck Biopharma Innovation Cup Honors Young Scientists Jul 26 2016
Merck (MRK) Q2 Earnings: Will the Stock Pull a Surprise? Jul 26 2016
Gilead Sciences Kicks Off 5 Big Pharma Earnings This Week Jul 25 2016
Germany plans to extend price brake for drugs under statutory insurance Jul 25 2016
Germany plans to extend price brake for drugs under statutory insurance Jul 25 2016
Eli Lilly’s Valuation Cheat Sheet for 2Q16 Jul 25 2016
Merck (MRK) Stock Down, Ebola Vaccine Under 'Accelerated' FDA Review Jul 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)